Select Bibliography

Filter by any of these (after searching):

Chen, Ronald

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 16 items

A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: an Alliance Foundation trial (AFT-19)

Aggarwal, Rahul , Eggener, Scott , Chen, Ronald , Heller, Glenn ... - ASCO - J Clin Oncol - 2018

Abstract - No-Endpoint - Trial-Description-Only - GU - AFT-19

Alliance A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (MIBC) (AMBASSADOR) vs Observation

Apolo, Andrea , Rosenberg, Jonathan , Morris, Michael ... - ASCO GU - J Clin Oncol - 2019

Abstract - No-Endpoint - Trial-Description-Only - GU - Alliance-A031501

Quality‐adjusted survival with first‐line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)

Chen, Ronald C. , Choueiri, Toni K. , Feuilly, Marion , Meng, Jie ... - - Cancer - 2020

Manuscript - Secondary-not-in-original - Primary - GU - Alliance-A031203

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab versus Avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001).

Gupta, Shilpa , Galsky, Matthew D. , Morris, Michael J. ... - ASCO - J Clin Oncol - 2022

Abstract - No-Endpoint - Trial-Description-Only - GU - Alliance-A032001

A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL / Alliance A031801)

McKay, Rana R. , Atherton, Pamela , Jacene, Heather ... - KCRS - - 2022

Abstract - No-Endpoint - Trial-Description-Only - GU - Alliance-A031801

Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum ineligible/refractory metastatic urothelial cancer

Nagar, Himanshu , Ballman, Karla , Tagawa, Scott T. , Tan, Alan ... - ASCO GU - J Clin Oncol - 2023

Abstract - No-Endpoint - Trial-Description-Only - GU - Alliance-A032002

Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Men’s Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance])

Parsons, J. Kellogg , Zahrieh, David , Patel, Devin ... - - Eur Urol Focus - 2022

Manuscript - Secondary - Primary - Prevention - CALGB-70807

Alliance A031902 (CASPAR): A randomized, phase 3 trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) in first-line metastatic castration-resistant prostate cancer (mCRPC)

Rao, Arpit , Heller, Glenn , Ryan, Charles J. ... - ASCO GU - J Clin Oncol - 2023

Abstract - No-Endpoint - Trial-Description-Only - GU - Alliance-A031902

Alliance A031902 (CASPAR): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).

Rao, Arpit , Heller, Glenn , Ryan, Charles J. ... - ASCO GU - J Clin Oncol - 2022

Abstract - No-Endpoint - Trial-Description-Only - GU - Alliance-A031902

CASPAR (Alliance A031902) - A Randomized, Phase III Trial of Enzalutamide with/without Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Rao, Arpit , Ryan, Charles J , Vanderweele, David , Heller, Glenn ... - ASCO - J Clin Oncol - 2022

Abstract - No-Endpoint - Trial-Description-Only - GU - Alliance-A031902

CASPAR (Alliance A031902) - A Randomized, Phase III Trial of Enzalutamide with/without Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Rao, Arpit , Ryan, Charles J , Vanderweele, David , Heller, Glenn ... - ASCO GU - J Clin Oncol - 2021

Abstract - No-Endpoint - Trial-Description-Only - GU - Alliance-A031902

Surveillance Imaging vs Symptomatic Recurrence Detection and Survival in Stage II-III Breast Cancer (AFT-01)

Schumacher, Jessica R , Neuman, Heather B , Yu, Menggang ... - - J Natl Cancer Inst - 2022

Manuscript - Primary - Primary - CCDR - AFT-01

PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated REnal Cell CancEr (Alliance A031704)

Zhang, Tian , Ballman, Karla , Choudhury, Atish , Chen, Ronald C. ... - ASCO - J Clin Oncol - 2020

Abstract - No-Endpoint - Trial-Description-Only - GU - Alliance-A031704

PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated REnal Cell CancEr (Alliance A031704)

Zhang, Tian , Ballman, Karla , Choudhury, Atish , Chen, Ronald C. ... - ASCO GU - J Clin Oncol - 2021

Abstract - No-Endpoint - Trial-Description-Only - GU - Alliance-A031704

PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated REnal Cell CancEr (Alliance A031704)

Zhang, Tian , Ballman, Karla , Choudhury, Atish , Chen, Ronald C. ... - IKCS - J Clin Oncol - 2020

Abstract - No-Endpoint - Trial-Description-Only - GU - Alliance-A031704

PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated REnal Cell CancEr (Alliance A031704)

Zhang, Tian , Ballman, Karla , Choudhury, Atish , Chen, Ronald C. ... - ASCO - J Clin Oncol - 2019

Abstract - No-Endpoint - Trial-Description-Only - GU - Alliance-A031704